International Cannabinoid Derived Pharmaceuticals (ICDP) Summit by Hanson Wade
In-Person Event
Dec 10 - 12, 2018
Boston, Massachusetts, USA
OVERVIEW
International Cannabinoid Derived Pharmaceuticals (ICDP) Summit is organized by Hanson Wade and will be held from Dec 10 - 12, 2018 at Hyatt Regency Boston, Boston, Massachusetts, United States of America.
Conference Description :
We set about our mission is to provide the forum that brings together leaders from the companies who are developing the cutting-edge cannabinoidbased pharmaceuticals and the academics that are conducting the innovative research that also contributes to this exciting field.
Issues include formulating unique compounds that achieve required responses, that can be delivered effectively. Many also still face problems designing reliable clinical trials in a frequently changing regulatory environment. We’ll be sharing and discussing these issues in depth with industry leaders such as Adi Zulloff-Shani of Therapix and Catherine Jacobson of Tilray.
In addition to issues that come with the scientific advances, also come the commercial considerations. Including how to form a commercial strategy in a space with an uncertain regulatory environment. Similarly knowing how to use IP to its maximum potential to build a strong business foundation. Gary Hiller of Phytecs and Tamas Biro of the University of Debrechen will take apart these issues with us.
With 17 hours of content, we will be tackling the key issues from the benchside to commercialization. By considering a range of therapeutic areas, the conference is designed exclusively for the Cannabinoid drug developer. Our speakers will discuss complex Cannabinoid pharmacology, formulations, clinical trials, patient education and commercial challenges.
We’ll discuss the important issues that impact pipelines from early R&D through to commercialisation, by targeting 6 distinct areas :
• The complex multi-target pharmacology of Cannabinoids.
• Preclinical formulation and drug delivery system design.
• The potential of Cannabinoids in meeting currently unmet clinical needs.
• Designing effective clinical trials and navigating the regulatory landscape.
• Understanding stakeholder perspectives and how we can better educate patients.
• The challenges companies face in funding, commercial strategy and IP.
Additional details will be posted as soon as they are available.
Conference Description :
We set about our mission is to provide the forum that brings together leaders from the companies who are developing the cutting-edge cannabinoidbased pharmaceuticals and the academics that are conducting the innovative research that also contributes to this exciting field.
Issues include formulating unique compounds that achieve required responses, that can be delivered effectively. Many also still face problems designing reliable clinical trials in a frequently changing regulatory environment. We’ll be sharing and discussing these issues in depth with industry leaders such as Adi Zulloff-Shani of Therapix and Catherine Jacobson of Tilray.
In addition to issues that come with the scientific advances, also come the commercial considerations. Including how to form a commercial strategy in a space with an uncertain regulatory environment. Similarly knowing how to use IP to its maximum potential to build a strong business foundation. Gary Hiller of Phytecs and Tamas Biro of the University of Debrechen will take apart these issues with us.
With 17 hours of content, we will be tackling the key issues from the benchside to commercialization. By considering a range of therapeutic areas, the conference is designed exclusively for the Cannabinoid drug developer. Our speakers will discuss complex Cannabinoid pharmacology, formulations, clinical trials, patient education and commercial challenges.
We’ll discuss the important issues that impact pipelines from early R&D through to commercialisation, by targeting 6 distinct areas :
• The complex multi-target pharmacology of Cannabinoids.
• Preclinical formulation and drug delivery system design.
• The potential of Cannabinoids in meeting currently unmet clinical needs.
• Designing effective clinical trials and navigating the regulatory landscape.
• Understanding stakeholder perspectives and how we can better educate patients.
• The challenges companies face in funding, commercial strategy and IP.
Additional details will be posted as soon as they are available.
KEY DATES
10 Dec, 2018
Event Start Date
12 Dec, 2018
Event End Date
SPECIALITIES
Pharmacy and MedicineSUGGESTED HOTELS
CONFERENCE VENUE
Hyatt Regency BostonRELATED CONFERENCES & LIVE WEBINARS
Quick Links